医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Targeted Medical Pharma Announces New Partnership for Exclusive Distribution in Japan

2015年02月20日 AM03:00
このエントリーをはてなブックマークに追加


 

LOS ANGELES

Targeted Medical Pharma (OTCQB: TRGM) today announced the completion of an exclusive product distribution agreement with J-Network Inc., a California-based company that specializes in distributing cosmetic and healthcare goods exclusively to Japan.

The Agreement grants J-Network an exclusive one-year renewable license for the marketing and sales of the Company’s proprietary product, designed to improve sleep and immune function, in Japan. Under the terms of the Agreement, Targeted Medical Pharma will develop new products specific for import into the Japanese market, and J-network is responsible for a guaranteed initial order of 360,000 capsules as well as maintaining annual minimum purchase orders of 1.4 million capsules for the first two years, and 2.1 million capsules thereafter.

This is the second partnership between Targeted Medical Pharma and J-Network. From 2007 to 2011, the J-Network successfully marketed Targeted Medical Pharma’s products to a variety of consumer groups throughout Japan.

“The completion of this agreement represents management’s renewed commitment to developing new revenue-generating opportunities abroad,” said Kim Giffoni, Chief Executive at Targeted Medical Pharma. “J-Network is a reliable and honorable business partner who understands the value of our product line and has a successful track record of distributing our products in Japan.”

Connect with us on Google Plus, Linkedin, Twitter and Facebook.

About Targeted Medical Pharma, Inc.

Targeted Medical Pharma, Inc. is a Los Angeles-based biotechnology company that develops medical foods for the treatment of chronic disease, including pain syndromes, peripheral neuropathy, hypertension, obesity, sleep and cognitive disorders. The company also develops a line of dietary supplements designed to support health and wellness. The company manufactures 10 proprietary medical foods, and the dietary supplement for sinus and immune support, Clearwayz™. The products are sold directly to physicians, patients and pharmacies in the United States and abroad.

Forward-Looking Statement

This press release may contain forward-looking statements related to Targeted Medical Pharma’s business strategy, outlook, objectives, plans, intentions or goals. Targeted Medical Pharma expressly disclaims any obligation or undertaking to update or revise any forward-looking statement contained herein to reflect any change in the company’s expectations with regard thereto or any change in events, conditions or circumstances upon which any statement is based.

CONTACT

Company Contact:
Targeted
Medical Pharma

Marcus Charuvastra, 310-474-9809
marcusch@tmedpharma.com
or
Investor
Contact:

Targeted Medical Pharma
William B.
Horne, 310-474-9809
whorne@tmedpharma.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • 武田和Seattle Genetics呈报3期ECHELON-1临床试验的阳性数据,该试验评估ADCETRIS® (brentuximab vedotin)用于晚期霍奇金淋巴瘤的一线治疗
  • ADCセラピューティクスが当社の新規抗体薬物複合体ADCT-301の第I相中間データを発表
  • Intercell USA Changes Name to Valneva USA, Inc. and Expands Commercial Presence
  • ADC Therapeutics präsentiert Zwischenergebnisse aus Phase-I-Studie zu neuartigem Antikörper-Wirkstoff-Konjugat ADCT-402
  • Bertin与Zymo Research宣布达成新的合作